Pulmonary Hypertension Summit Webcasts
Pulmonary Arterial Hypertension Updates
Release date: 3/16/25
Expiration date: 3/15/27
Estimated Time of Completion: 3 hours
Session Agenda
PH Definition and Classification – How do I deal with Comorbidities?
David Badesch, MD,UCHealth University of Colorado Hospital
Risk Stratification in PAH – what is new?
Raymond L. Benza, MD, FACC, FAHA, FACP,Icahn School of Medicine at Mount Sinai
Updated PAH Treatment Algorithm
Vallerie McLaughlin, MD,
University of Michigan Health
The new kid on the (treatment) block – Sotatercept for PAH
PH Definition and Classification – How do I deal with Comorbidities?
David Badesch, MD,
UCHealth University of Colorado Hospital
Panel Discussion: Put it all together
Moderator: Roger Alvarez, DO, MPH, MS
Panel: David Badesch, MD, Raymond Benza, MD, FACC, FAHA, FACP, Vallerie McLauglin , MD
Description
Watch Pulmonary Hypertension Summit on-demand webcast series, recorded from the 2025 Pulmonary Hypertension Summit. The focus of the education is to provide you with an overview of the practical issues in the diagnosis, evaluation, and management of patients with pulmonary hypertension. Expert speakers present the most recent advances in the context of challenges faced by physicians and other health care providers caring for these patients. Additionally, the education addresses advances in diagnosis and risk stratification, emerging therapeutics, management of populations with concomitant disease, and technological innovations.
Faculty Disclosure
In accordance with the Standards for Integrity and Independence issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Center for Continuing Education mitigates all relevant conflicts of interest to ensure CME activities are free of commercial bias. All relevant financial relationships have been mitigated.
The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:
Roger A Alvarez, DO | |
United Therapeutics Corporation | Consulting Teaching and Speaking Research |
David Badesch, MD | |
Merck | Consulting |
Johnson & Johnson | Ownership interest (stock, stock options in a publicly owned company) |
United Therapeutics Corporation | Research |
Pfizer | Research |
AI Therapeutics | Research |
Raymond Benza, MD | |
Abbott | Consulting |
Neal Chaisson, MD | |
United Therapeutics Corporation | Consulting Teaching and Speaking |
Bayer | Advisor or review panel participant Teaching and Speaking |
Gustavo Heresi-Davila, MD | |
Bayer Healthcare | Advisor of review panel participant Teaching and Speaking Research |
Janssen Research & Development, LLC | Advisor or review panel participant |
Vallerie McLaughlin, MD | |
Aerovate | Consulting Research |
Enzyvant Therapeutics GmpH | Research |
Gossamer Bio | Consulting Research |
Keros Therapeutics | Consulting Research |
Sonovie | Research |
Janssen | Consulting Research |
Merck | Consulting Research |
Apollo | Consulting |
CVS/Caremark | Consulting |
Corvista | Consulting |
Liquidia | Consulting |
Morphic Therapeutics | Consulting |
Regeneron | Consulting |
Respira | Consulting |
Riovant | Consulting |
United Therapeutics Corporation | Consulting |
Mindy Leann Rivera, CNS | |
Janssen | Consulting Teaching and Speaking |
United Therapeutics Corporation | Consulting Teaching and Speaking |
All other individuals have indicated no relationship which, in the context of their involvement, could be perceived as a potential conflict of interest.
Acknowledgment
The Cleveland Clinic Center for Continuing Education acknowledges educational grants for partial support of this activity from:
Bayer HealthCare Pharmaceuticals Inc.
ST Shared Services LLC, a Mallinckrodt company
Actelion Pharmaceuticals US, Inc.
United Therapeutics Corporation
This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education and Cleveland Clinic’s Hospital Based Care Institute.